#$%^&*AU2019284060A120200123.pdf#####ABSTRACT The invention provides a controlled release oral formulation comprising (a) a controlled release component comprising core comprising levodopa and/or an ester of levadopa or salts thereof, wherein the core is coated with a layer of a muco-adhesive polymer and externally coated with a layer of an enteric coated polymer and (b) a decarboxylase inhibitor component. 58